Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-09-10 Director's Dealing
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 99% confidence The document text details transactions conducted by a person discharging managerial responsibilities ('Jan Haudemann-Andersen', a 'Board Member') concerning shares in the issuer ('Vaccibody AS'). Specifically, it reports the 'Sale of shares to closely associated enterprise' on a specific date (10.09.2021). This structure—reporting personal transactions by directors/executives—is the defining characteristic of a Director's Dealing report, which corresponds to the code DIRS.
2021-09-10 English
Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Mandatory notification of intra group transfer of shares by primary insider’s related party'. It details share transactions (sales and purchases) involving entities related to a board member (Jan Haudemann-Andersen) of Vaccibody AS. This directly corresponds to the definition of Director's Dealing (insider trades) or a notification of changes in significant share ownership. Since the focus is on the transactions by the insider's related parties, the most specific category is 'Director's Dealing' (DIRS). It is not a general regulatory filing (RNS) because a more specific category exists, and it is not a Major Shareholding Notification (MRQ) as it details insider transactions rather than just crossing a threshold.
2021-09-10 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Share capital increase from exercise of warrants' and details the resulting change in the number of outstanding shares and the total share capital. This directly relates to changes in the company's capital structure due to the issuance of new shares following warrant exercise. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). The document is short, but its content is a direct announcement of a capital change, not just an announcement *about* a report.
2021-09-07 English
Vaccibody AS - Quarterly report Q2 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled '2nd Quarter 2021 Report' and contains comprehensive financial statements, including the income statement, statement of financial position, cash flow, and notes to the interim financial statements. It also includes a management discussion of financial results and R&D updates. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q2 2021
2021-08-26 English
Vaccibody AS - Quarterly report Q2 2021
Report Publication Announcement Classification · 99% confidence The document is titled 'Vaccibody AS - Quarterly report Q2 2021' and announces the second quarter 2021 results. However, the text explicitly states: 'The second quarter 2021 report will be available at https://www.vaccibody.com/financial-reports-and-presentations/'. This indicates the document itself is not the comprehensive quarterly report (which would be classified as IR), but rather a short announcement informing the public that the report has been published or is available elsewhere. Given the short length (2565 characters) and the nature of the announcement pointing to the full report, this fits the definition of a Report Publication Announcement (RPA).
2021-08-26 English
Vaccibody Q2 and half-year report 2021 webcast
Report Publication Announcement Classification · 98% confidence The document is a short announcement dated August 23, 2021, titled "Vaccibody Q2 and half-year report 2021 webcast." It explicitly states that the company will hold a webcast on August 26, 2021, to discuss the results for the first half of 2021, and provides a link to the webcast and mentions where the slide presentation will be available. This structure—announcing the release/discussion of a report (the half-year report) rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). The document length (2752 chars) is also very short, supporting the 'MENU VS MEAL' rule.
2021-08-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.